Relmada Therapeutics, Inc. (RLMD): Operating Cash Flow
-$45.79M
Year ended 2025-12-31
-$45.99M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$45.79M | n/m | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | -$51.76M | n/m | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | -$51.66M | n/m | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | -$103.80M | n/m | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | -$91.87M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | -$27.81M | n/m | 2022-03-25, From 2020-01-01 |
| 2019-12-31 | -$12.09M | n/a | 2021-03-24, From 2019-01-01 |
| No annual figure between 2018-06-30 and 2019-12-31. | |||
| 2018-06-30 | -$6.00M | n/m | 2019-09-24, From 2017-07-01 |
| 2017-06-30 | -$6.47M | n/m | 2018-09-28, From 2016-07-01 |
| 2016-06-30 | -$13.14M | n/m | 2017-09-28, From 2015-07-01 |
| 2015-06-30 | -$16.23M | n/a | 2016-09-09, From 2014-07-01 |
| No annual figure between 2013-12-31 and 2015-06-30. | |||
| 2013-12-31 | -$2.24M | n/a | 2015-09-11, From 2013-01-01 |
| No annual figure between 2012-08-31 and 2013-12-31. | |||
| 2012-08-31 | -$7.6K | n/a | 2013-12-16, From 2011-09-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | -$45.79M | n/m |
| Journey Medical Corp (DERM) | 2025-12-31 | -$12.44M | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$39.64M | n/m |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $10.52M | +986.1% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$63.50M | n/m |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | -$39.88M | n/m |
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | -$13.51M | n/m |
| Dogwood Therapeutics, Inc. (DWTX) | 2025-12-31 | -$15.62M | n/m |
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | -$25.25M | n/m |
Compare RLMD, DERM, ABUS, ETON side by side · Screen every company in Pharmaceutical Preparations ↗